Tourmaline Bio (TRML) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
On October 19, 2023, the Delaware corporation previously known as Talaris Therapeutics, Inc. finalized its merger with Legacy Tourmaline, now known as Tourmaline Sub, Inc., making it a direct wholly owned subsidiary. Post-merger, the company adopted the name Tourmaline Bio, Inc. and shifted its primary business focus to the operations previously conducted by Legacy Tourmaline.
For further insights into TRML stock, check out TipRanks’ Stock Analysis page.